Meglumine cyclic adenylate improves neurological function following acute spinal cord injury in rats

Liao,Jingwu; Xie,Jingming; Lin,Daqiang; Lu,Ning; Guo,Limin; Li,Weiqiang; Pu,Bo; Yang,Yang; Yang,Zhenlong; Zhang,Ying; Song,Yueming

doi:10.3892/mmr.2014.2352

Meglumine cyclic adenylate improves neurological function following acute spinal cord injury in rats

Authors:
- Jingwu Liao
- Jingming Xie
- Daqiang Lin
- Ning Lu
- Limin Guo
- Weiqiang Li
- Bo Pu
- Yang Yang
- Zhenlong Yang
- Ying Zhang
- Yueming Song
View Affiliations

Affiliations: Department of Orthopaedic Surgery, The 2nd Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650031, P.R. China, Department of Orthopaedic Surgery, Hospital of Integrated Traditional and Western Medicine, Dazhou, Sichuan 635000, P.R. China, Department of Orthopaedic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: June 25, 2014 https://doi.org/10.3892/mmr.2014.2352
Pages: 1225-1230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Elevation of intracellular cyclic adenosine monophosphate (cAMP) levels facilitates recovery following spinal injury by suppressing secondary pathology and promoting axonal regeneration. However, this treatment strategy is limited by lack of effective and tolerable clinical agents. The present study examined the effects of meglumine cyclic adenylate (MCA) on neurological recovery, cAMP concentration, adenylate cyclase 3 (AC3) activity and phosphodiesterase 4D (PDE4D) activity during early stage acute spinal cord injury (SCI) in rats. A total of 48 Sprague‑Dawley rats were randomly assigned to groups A, B or C, each consisting of 16 animals. SCI was induced by Allen's method using a 7 g x 3 cm extradural weight‑drop impact on spinal cord segment T11. A total of 30 min following SCI, group A received a single 30 mg/kg‑bw i.p. dose of methylprednisolone, group B received 2 mg/kg‑bw i.p. MCA daily for seven days and group C were administered an equal volume of normal saline. Seven days following SCI, the spinal cord samples from eight rats per group were obtained to measure the cAMP concentration, and the activities of AC3 and PDE4D. The remaining eight rats per group were used for behavioral assessments using the inclined plane stability test and Gale scale for up to six weeks post‑SCI. The drug‑treated groups A and B had higher cAMP concentrations and AC3 activities but lower PDE4D activities at the lesion sites, as well as superior behavioral scores post‑SCI compared with the vehicle‑treated group C (P<0.05). Furthermore, cAMP was higher in group B than in group A (P<0.05). It was concluded that MCA may serve as an effective SCI treatment by activating AC3 and suppressing PDE4D.

View Figures

View References

1	Wiedemann C: Repair: CSI in SCI. Nat Rev Neurosci. 10:6212009. View Article : Google Scholar
2	Cripps RA, Lee BB, Wing P, et al: A global map for traumatic spinal cord injury epidemiology: towards a living data repository for injury prevention. Spinal Cord. 49:493–501. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ito Y, Sugimoto Y, Tomioka M, Kai N and Tanaka M: Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury?: a prospective study about neurological recovery and early complications. Spine (Phila Pa 1976). 34:2121–2124. 2009. View Article : Google Scholar
4	Bracken M: Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 3:CD0010462002.
5	Baptiste DC and Fehlings MG: Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 13:63–80. 2008. View Article : Google Scholar : PubMed/NCBI
6	Kwon BK, Hillyer J and Tetzlaff W: Translational research in spinal cord injury: a survey of opinion from the SCI community. J Neurotrauma. 27:21–33. 2010. View Article : Google Scholar : PubMed/NCBI
7	Abe N and Cavalli V: Nerve injury signaling. Curr Opin Neurobiol. 18:276–283. 2008. View Article : Google Scholar : PubMed/NCBI
8	Udina E, Ladak A, Furey M, et al: Rolipram-induced elevation of cAMP or chondroitinase ABC breakdown of inhibitory proteoglycans in the extracellular matrix promotes peripheral nerve regeneration. Exp Neurol. 223:143–152. 2010. View Article : Google Scholar
9	Hannila SS and Filbin MT: The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol. 209:321–332. 2008. View Article : Google Scholar : PubMed/NCBI
10	Mekhail M, Almazan G and Tabrizian M: Oligodendrocyte-protection and remyelination post-spinal cord injuries: a review. Prog Neurobiol. 96:322–339. 2012. View Article : Google Scholar : PubMed/NCBI
11	Gancedo JM: Biological roles of cAMP: variations on a theme in the different kingdoms of life. Biol Rev Camb Philos Soc. 88:645–668. 2013. View Article : Google Scholar : PubMed/NCBI
12	Seifert R, Lushington GH, Mou TC, Gille A and Sprang SR: Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci. 33:64–78. 2012. View Article : Google Scholar : PubMed/NCBI
13	Michalski JM, Golden G, Ikari J and Rennard SI: PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther. 91:134–142. 2012. View Article : Google Scholar : PubMed/NCBI
14	Whitaker CM, Beaumont E, Wells MJ, et al: Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci Lett. 438:200–204. 2008. View Article : Google Scholar
15	Pavan B, Paganetto G and Dalpiaz A: Dopamine-sensitive adenylyl cyclases in neuronal development: physiopathological and pharmacological implications. Drug Discov Today. 16:520–529. 2011. View Article : Google Scholar
16	Col JA, Matsuo T, Storm DR and Rodriguez I: Adenylyl cyclase-dependent axonal targeting in the olfactory system. Development. 134:2481–2489. 2007. View Article : Google Scholar : PubMed/NCBI
17	Koozekanani SH, Vise WM, Hashemi RM and McGhee RB: Possible mechanisms for observed pathophysiological variability in experimental spinal cord injury by the method of Allen. J Neurosurg. 44:429–434. 1976. View Article : Google Scholar
18	Rivlin AS and Tator CH: Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg. 47:577–581. 1977. View Article : Google Scholar : PubMed/NCBI
19	Gale K, Kerasidis H and Wrathall JR: Spinal cord contusion in the rat: behavioral analysis of functional neurologic impairment. Exp Neurol. 88:123–134. 1985. View Article : Google Scholar : PubMed/NCBI
20	Gilman AG: Silver spoons and other personal reflections. Annu Rev Pharmacol Toxicol. 52:1–19. 2012. View Article : Google Scholar : PubMed/NCBI
21	Song XJ, Wang ZB, Gan Q and Walters ET: cAMP and cGMP contribute to sensory neuron hyperexcitability and hyperalgesia in rats with dorsal root ganglia compression. J Neurophysiol. 95:479–492. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bhatt DH, Otto SJ, Depoister B and Fetcho JR: Cyclic AMP-induced repair of zebrafish spinal circuits. Science. 305:254–258. 2004. View Article : Google Scholar : PubMed/NCBI
23	Nikulina E, Tidwell JL, Dai HN, Bregman BS and Filbin MT: The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci USA. 101:8786–8790. 2004. View Article : Google Scholar : PubMed/NCBI
24	Pearse DD, Pereira FC, Marcillo AE, et al: cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med. 10:610–616. 2004. View Article : Google Scholar : PubMed/NCBI
25	Page CP and Spina D: Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 12:275–286. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhu J, Yang Q, Dai D and Huang Q: X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. J Am Chem Soc. 135:11708–11711. 2013. View Article : Google Scholar
27	Liu S, Li Y, Kim S, et al: Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein-coupled receptors in hearts. Proc Natl Acad Sci USA. 109:6578–6583. 2012. View Article : Google Scholar : PubMed/NCBI
28	Perez-Torres S, Miro X, Palacios JM, et al: Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat. 20:349–374. 2000.PubMed/NCBI
29	Lamontagne S, Meadows E, Luk P, et al: Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 920:84–96. 2001. View Article : Google Scholar : PubMed/NCBI
30	Abaffy T, Trubey KR and Chaudhari N: Adenylyl cyclase expression and modulation of cAMP in rat taste cells. Am J Physiol Cell Physiol. 284:C1420–C1428. 2003. View Article : Google Scholar : PubMed/NCBI
31	Gavaldà A and Roberts RS: Phosphodiesterase-4 inhibitors: a review of current developments (2010–2012). Expert Opin Ther Pat. 23:997–1016. 2013.PubMed/NCBI
32	Wu D, Zhao Y, Yang Y, Wang W and Xu R: [A multicenter clinical study on clinical effects of meglumine cyclic adenylate in treating patients with chronic pulmonary heart disease]. Zhonghua nei ke za zhi. 40:467–470. 2001.(In Chinese).
33	Xing SH, Gu SL and Meng QC: Meglumine cyclic adenylate pediatric dosage calculations. XuZhou Acta Academiae Medicinae. 19:370–372. 1999.